Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Centessa’s OX2R agonist pipeline features a potential best-in-class therapeutic with important promise to meaningfully enhance outcomes throughout a spread of sleep-wake disorders Acquisition expands Lilly’s neuroscience portfolio and capabilities into sleep drugs INDIANAPOLIS and BOSTON and LONDON, March 31, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a…

Read More